UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2022

 

Commission file number: 001-40231

 

Universe Pharmaceuticals INC 

 

265 Jingjiu Avenue

Jinggangshan Economic and Technological Development Zone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

Explanatory Note

 

Universe Pharmaceuticals INC (the “Registrant”) is filing this current report on Form 6-K to report its financial results for the six months ended August 16, 2022 and to discuss its recent corporate developments.

 

Attached as exhibits to this current report on Form 6-K are:

 

  (1) the unaudited condensed interim consolidated financial statements and related notes as Exhibit 99.1;
     
  (2) Management’s Discussion and Analysis of Financial Condition and Results of Operations as Exhibit 99.2;
     
  (3) a press release dated August 12, 2022, titled “Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2022” as Exhibit 99.3; and
     
  (4) Interactive Data File disclosure as Exhibit 101 in accordance with Rule 405 of Regulation S-T.

 

1

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Statements in this current report with respect to the Company’s current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of the Company. Forward-looking statements include, but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,” “seek,” “may,” “might,” “could” or “should,” and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the U.S. Securities and Exchange Commission. Therefore, investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements.

 

All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

  

2

 

 

EXHIBIT INDEX

 

Exhibit

No.

  

Description

99.1   Unaudited Consolidated Financial Statements and Related Notes As of March 31, 2022 and for the Six Months Ended March 31, 2022 and 2021
99.2   Management’s Discussion and Analysis of Financial Condition and Results of Operations
99.3   Press Release – Universe Pharmaceuticals INC Reports Fiscal Year 2021 Financial Results
101.INS   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Universe Pharmaceuticals INC.
   
Date: August 16, 2022 By: /s/ Gang Lai
    Gang Lai
    Chief Executive Officer

 

 

4

 

 

false --09-30 2022-03-31 0001809616 0001809616 2021-10-01 2022-03-31 0001809616 2022-03-31 0001809616 2021-09-30 0001809616 2020-10-01 2021-03-31 0001809616 us-gaap:CommonStockMember 2020-09-30 0001809616 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001809616 upc:SubscriptionReceivableMember 2020-09-30 0001809616 upc:StatutoryReservesMember 2020-09-30 0001809616 us-gaap:RetainedEarningsMember 2020-09-30 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001809616 2020-09-30 0001809616 us-gaap:CommonStockMember 2020-10-01 2021-03-31 0001809616 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-03-31 0001809616 upc:SubscriptionReceivableMember 2020-10-01 2021-03-31 0001809616 upc:StatutoryReservesMember 2020-10-01 2021-03-31 0001809616 us-gaap:RetainedEarningsMember 2020-10-01 2021-03-31 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2021-03-31 0001809616 us-gaap:CommonStockMember 2021-03-31 0001809616 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001809616 upc:SubscriptionReceivableMember 2021-03-31 0001809616 upc:StatutoryReservesMember 2021-03-31 0001809616 us-gaap:RetainedEarningsMember 2021-03-31 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001809616 2021-03-31 0001809616 us-gaap:CommonStockMember 2021-09-30 0001809616 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001809616 upc:SubscriptionReceivableMember 2021-09-30 0001809616 upc:StatutoryReservesMember 2021-09-30 0001809616 us-gaap:RetainedEarningsMember 2021-09-30 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001809616 us-gaap:CommonStockMember 2021-10-01 2022-03-31 0001809616 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-03-31 0001809616 upc:SubscriptionReceivableMember 2021-10-01 2022-03-31 0001809616 upc:StatutoryReservesMember 2021-10-01 2022-03-31 0001809616 us-gaap:RetainedEarningsMember 2021-10-01 2022-03-31 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2022-03-31 0001809616 us-gaap:CommonStockMember 2022-03-31 0001809616 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001809616 upc:SubscriptionReceivableMember 2022-03-31 0001809616 upc:StatutoryReservesMember 2022-03-31 0001809616 us-gaap:RetainedEarningsMember 2022-03-31 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001809616 upc:UniverseHKMember 2021-10-01 2022-03-31 0001809616 upc:UniverseIncMember 2022-03-31 0001809616 upc:UniverseTechnologyMember 2022-03-31 0001809616 upc:UniverseTechnologyMember 2019-12-01 2019-12-31 0001809616 upc:JiangxiUniverseMember 2021-10-01 2022-03-31 0001809616 upc:UniverseTradeMember 2022-03-31 0001809616 upc:JiangxiMember 2022-03-31 0001809616 2021-03-25 0001809616 us-gaap:OverAllotmentOptionMember 2021-03-29 0001809616 2021-03-25 2021-03-25 0001809616 us-gaap:OverAllotmentOptionMember 2021-03-25 2021-03-25 0001809616 upc:UniverseIncMember 2021-10-01 2022-03-31 0001809616 upc:UniverseHKMember 2021-10-01 2022-03-31 0001809616 upc:UniverseHKMember 2022-03-31 0001809616 upc:UniverseTechnologyMember 2021-10-01 2022-03-31 0001809616 upc:UniverseTechnologyMember 2022-03-31 0001809616 upc:JiangxiUniverseMember 2021-10-01 2022-03-31 0001809616 upc:JiangxiUniverseMember 2022-03-31 0001809616 upc:UniverseTradeMember 2021-10-01 2022-03-31 0001809616 upc:UniverseHanheMember 2021-10-01 2022-03-31 0001809616 upc:UniverseHanheMember 2022-03-31 0001809616 2020-10-01 2021-09-30 0001809616 upc:UniversePharmaceuticalsINCMember 2022-03-31 0001809616 upc:JxRcbBankMember 2021-10-01 2022-03-31 0001809616 upc:JxRcbBankMember 2022-03-31 0001809616 us-gaap:OtherLongTermInvestmentsMember 2021-10-01 2022-03-31 0001809616 us-gaap:OtherLongTermInvestmentsMember 2020-10-01 2021-09-30 0001809616 pf0:MinimumMember 2018-04-25 2018-05-01 0001809616 pf0:MinimumMember 2019-03-25 2019-04-01 0001809616 us-gaap:BuildingMember 2021-10-01 2022-03-31 0001809616 pf0:MinimumMember us-gaap:MachineryAndEquipmentMember 2021-10-01 2022-03-31 0001809616 pf0:MaximumMember us-gaap:MachineryAndEquipmentMember 2021-10-01 2022-03-31 0001809616 pf0:MinimumMember us-gaap:AutomobilesMember 2021-10-01 2022-03-31 0001809616 pf0:MaximumMember us-gaap:AutomobilesMember 2021-10-01 2022-03-31 0001809616 pf0:MinimumMember upc:OfficeAndElectricEquipmentMember 2021-10-01 2022-03-31 0001809616 pf0:MaximumMember upc:OfficeAndElectricEquipmentMember 2021-10-01 2022-03-31 0001809616 us-gaap:UseRightsMember 2021-10-01 2022-03-31 0001809616 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-10-01 2022-03-31 0001809616 upc:LessThan3MonthsMember 2022-03-31 0001809616 upc:LessThan3MonthsMember 2021-10-01 2022-03-31 0001809616 upc:From4To6MonthsMember 2022-03-31 0001809616 upc:From4To6MonthsMember 2021-10-01 2022-03-31 0001809616 upc:From7To9MonthsMember 2022-03-31 0001809616 upc:From7To9MonthsMember 2021-10-01 2022-03-31 0001809616 upc:From10To12MonthsMember 2022-03-31 0001809616 upc:From10To12MonthsMember 2021-10-01 2022-03-31 0001809616 upc:Over1YearMember 2022-03-31 0001809616 upc:Over1YearMember 2021-10-01 2022-03-31 0001809616 2021-09-01 2021-09-06 0001809616 2021-09-06 0001809616 us-gaap:BuildingMember 2022-03-31 0001809616 us-gaap:BuildingMember 2021-09-30 0001809616 us-gaap:MachineryAndEquipmentMember 2022-03-31 0001809616 us-gaap:MachineryAndEquipmentMember 2021-09-30 0001809616 us-gaap:AutomobilesMember 2022-03-31 0001809616 us-gaap:AutomobilesMember 2021-09-30 0001809616 upc:OfficeAndElectricEquipmentMember 2022-03-31 0001809616 upc:OfficeAndElectricEquipmentMember 2021-09-30 0001809616 us-gaap:ConstructionInProgressMember 2022-03-31 0001809616 us-gaap:ConstructionInProgressMember 2021-09-30 0001809616 us-gaap:UseRightsMember 2022-03-31 0001809616 us-gaap:UseRightsMember 2021-09-30 0001809616 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-03-31 0001809616 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-09-30 0001809616 upc:AmortizationExpenseMember 2022-03-31 0001809616 us-gaap:ConstructionInProgressMember 2021-06-25 0001809616 upc:ChenyuanMember 2022-03-31 0001809616 us-gaap:ConstructionInProgressMember upc:ChenyuanMember 2022-03-31 0001809616 upc:CapitalExpenditureMember 2022-03-31 0001809616 upc:MrGangLaiMember 2021-05-06 0001809616 2021-05-06 0001809616 2021-05-01 2021-05-06 0001809616 upc:JiangxiLulingRuralCommercialBankMember 2021-06-16 0001809616 upc:JiangxiLulingRuralCommercialBankMember 2021-06-01 2021-06-16 0001809616 2021-06-01 2021-06-16 0001809616 2021-06-16 0001809616 2021-06-30 0001809616 2021-06-01 2021-06-30 0001809616 2021-03-18 0001809616 2021-03-01 2021-03-18 0001809616 upc:MaturityGreaterThan90DaysOneMember 2022-03-31 0001809616 upc:MaturityGreaterThan90DaysOneMember 2021-09-30 0001809616 upc:MaturityGreaterThan90DaysTwoMember 2022-03-31 0001809616 upc:MaturityGreaterThan90DaysTwoMember 2021-09-30 0001809616 upc:MaturityGreaterThan90DaysThreeMember 2022-03-31 0001809616 upc:MaturityGreaterThan90DaysThreeMember 2021-09-30 0001809616 upc:MaturityGreaterThan90DaysFourMember 2022-03-31 0001809616 upc:MaturityGreaterThan90DaysFourMember 2021-09-30 0001809616 upc:MrGangLaiMember 2021-10-01 2022-03-31 0001809616 upc:MsLinYangMember 2021-10-01 2022-03-31 0001809616 upc:GreatestGroupMember 2021-10-01 2022-03-31 0001809616 upc:FoshanShangyuMember 2021-10-01 2022-03-31 0001809616 upc:GreatestGroupMember 2022-03-31 0001809616 upc:GreatestGroupMember 2021-09-30 0001809616 upc:FoshanShangyuMember 2022-03-31 0001809616 upc:FoshanShangyuMember 2021-09-30 0001809616 upc:MrGangLaiMember 2022-03-31 0001809616 upc:MrsLinYangMember 2021-09-30 0001809616 country:HK 2021-10-01 2022-03-31 0001809616 country:HK 2020-10-01 2021-03-31 0001809616 country:KY 2021-10-01 2022-03-31 0001809616 country:KY 2020-10-01 2021-03-31 0001809616 country:CN 2021-10-01 2022-03-31 0001809616 country:CN 2020-10-01 2021-03-31 0001809616 upc:CustomerMember 2021-10-01 2022-03-31 0001809616 upc:CustomerMember 2020-10-01 2021-03-31 0001809616 upc:TotalRevenueMember 2021-10-01 2022-03-31 0001809616 upc:TotalRevenueMember 2020-10-01 2021-03-31 0001809616 upc:GubenYanlingPillMember 2021-10-01 2022-03-31 0001809616 upc:GubenYanlingPillMember 2020-10-01 2021-03-31 0001809616 us-gaap:AccountsReceivableMember 2021-10-01 2022-03-31 0001809616 us-gaap:AccountsReceivableMember 2020-10-01 2021-09-30 0001809616 upc:SupplierOneMember 2021-10-01 2022-03-31 0001809616 upc:SupplierTwoMember 2021-10-01 2022-03-31 0001809616 upc:SupplierOneMember 2020-10-01 2021-09-30 0001809616 upc:SupplierTwoMember 2020-10-01 2021-09-30 0001809616 upc:supplierMember 2021-10-01 2022-03-31 0001809616 upc:SupplierOneMember 2020-10-01 2021-03-31 0001809616 upc:SupplierTwoMember 2020-10-01 2021-03-31 0001809616 upc:SupplierThreeMember 2020-10-01 2021-03-31 0001809616 upc:UniverseINCMember 2022-03-31 0001809616 upc:UniverseINCMember 2020-08-07 0001809616 upc:UniverseINCMember 2020-08-02 2020-08-07 0001809616 upc:UniverseINCMember us-gaap:CommonStockMember 2021-10-01 2022-03-31 0001809616 us-gaap:IPOMember 2021-03-25 0001809616 us-gaap:IPOMember 2021-03-29 0001809616 us-gaap:IPOMember 2021-03-25 2021-03-25 0001809616 us-gaap:IPOMember 2022-03-31 0001809616 us-gaap:IPOMember 2021-09-30 0001809616 upc:UnderwriterWarrantsMember 2022-03-31 0001809616 upc:UnderwriterWarrantsMember 2021-10-01 2022-03-31 0001809616 upc:UnderwriterWarrantsMember us-gaap:IPOMember 2022-03-31 0001809616 upc:UnderwriterWarrantsMember 2022-03-31 0001809616 upc:CashDividendsMember 2016-09-02 2016-09-21 0001809616 upc:CashDividendsMember 2017-09-02 2017-09-13 0001809616 upc:CashDividendsMember 2018-01-28 2018-02-02 0001809616 upc:CashDividendsMember 2018-09-02 2018-09-20 0001809616 upc:CashDividendsMember 2019-02-02 2019-02-21 0001809616 upc:CashDividendsMember 2021-10-01 2022-03-31 0001809616 upc:StatutoryReserveAndRestrictedNetAssetsMember 2021-10-01 2022-03-31 0001809616 upc:StatutoryReserveAndRestrictedNetAssetsMember 2022-03-31 0001809616 upc:StatutoryReserveAndRestrictedNetAssetsMember 2021-09-30 0001809616 upc:StatutoryReserveAndRestrictedNetAssetsMember 2020-10-01 2021-09-30 0001809616 upc:PRCMember 2022-03-31 0001809616 upc:PRCMember 2021-03-31 0001809616 pf0:ChiefExecutiveOfficerMember 2021-10-01 2022-03-31 0001809616 us-gaap:CorporateMember 2021-10-01 2022-03-31 0001809616 us-gaap:CorporateMember 2020-10-01 2021-03-31 0001809616 upc:CorporateSegmentOneMember 2021-10-01 2022-03-31 0001809616 upc:CorporateSegmentOneMember 2020-10-01 2021-03-31 0001809616 upc:CorporateSegmentTwoMember 2021-10-01 2022-03-31 0001809616 upc:CorporateSegmentTwoMember 2020-10-01 2021-03-31 0001809616 upc:CorporateSegmentThreeMember 2021-10-01 2022-03-31 0001809616 upc:CorporateSegmentThreeMember 2020-10-01 2021-03-31 0001809616 upc:CorporateSegmentFourMember 2021-10-01 2022-03-31 0001809616 upc:CorporateSegmentFourMember 2020-10-01 2021-03-31 0001809616 upc:CorporateSegmentFiveMember 2021-10-01 2022-03-31 0001809616 upc:CorporateSegmentFiveMember 2020-10-01 2021-03-31 0001809616 upc:CorporateSegmentSixMember 2021-10-01 2022-03-31 0001809616 upc:CorporateSegmentSixMember 2020-10-01 2021-03-31 0001809616 pf0:ScenarioForecastMember upc:LRCBankMember 2022-06-15 0001809616 pf0:ScenarioForecastMember upc:LRCBankMember 2022-06-15 2022-06-15 0001809616 pf0:ScenarioForecastMember upc:BankOfCommunicationsMember 2022-06-24 0001809616 pf0:ScenarioForecastMember upc:BankOfCommunicationsMember 2022-06-24 2022-06-24 0001809616 us-gaap:ParentMember 2022-03-31 0001809616 us-gaap:ParentMember 2021-09-30 0001809616 us-gaap:ParentMember 2021-10-01 2022-03-31 0001809616 us-gaap:ParentMember 2020-10-01 2021-03-31 0001809616 us-gaap:ParentMember 2020-09-30 0001809616 us-gaap:ParentMember 2021-03-31 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure iso4217:CNY utr:sqm
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Universe Pharmaceuticals Charts.
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Universe Pharmaceuticals Charts.